ArticleDiscover oncology2025
Expression and mechanism of PRDXs family in oral squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical value and molecular role of PRDXs family in prostate cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOur study mainly focused on exploring the expression and mechanism of PRDXs family members in OSCC, as well as the diagnostic and prognostic monitoring value of PRDXs family members in OSCC.
methodWe used bioinformatics tools to perform and visualize gene differential analysis on OSCC, analyse the expression of PRDXs family members in OSCC, and evaluate the diagnostic and prognostic monitoring value of PRDXs family members in OSCC patients. We utilized UALCAN, Cbioportal, and STRING websites to analyze the expression and gene mutations of the PRDXs family in pan-cancer, as well as the correlation of PRDXs family members. We used RT-qPCR technology to analyze the expression of PRDXs family members in OSCC cells. We used CCK8 technology to analyze the effect of PRDXs family members on the proliferation of OSCC cells.
resultPRDX1, PRDX2, PRDX4 and PRDX5 are generally highly expressed in pan cancer, but PRDX6 is generally low expressed in pan-cancer. PRDX2 and PRDX6 have higher alteration frequency and the mutation of PRDXs family mainly focus on amplification in Pan-Cancer. PRDX1, PRDX4, and PRDX5 are highly expressed in OSCC tissue, while PRDX2 is low expressed in OSCC tissue. Similarly, PRDX1, PRDX4, and PRDX5 are also highly expressed in OSCC cells. Furthermore, PRDX1, PRDX4, and PRDX6 can promote the proliferation of OSCC cells. Except for PRDX6, all other members of the PRDXs family interact with TXN, and TXN plays a crucial role in the PRDXs family. PRDX4 has the highest diagnostic efficiency for OSCC, while PRDX2 and PRDX5 also have high diagnostic efficiency. The high expression of PRDX1 and PRDX6 suggests poor prognosis in OSCC patients, while the low expression of PRDX5 suggests poor prognosis in OSCC patients.
conclusionPRDXs family members are expressed to varying degrees in OSCC and have different diagnostic and prognostic monitoring values for OSCC, which may provide a new direction for the clinical diagnosis and treatment of OSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.